[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529513":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":36,"locations":47,"responsibleParty":65,"collaborators":26,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":26,"enrollmentInfo":77,"targetDuration":26,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":26,"overallStatus":50,"whyStopped":26,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Ottawa Heart Institute Research Corporation","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment","EXPERIMENTAL","Dapagliflozin 10mg daily X 7 days",[13,14],"Drug: Dapagliflozin 10mg Tab","Diagnostic Test: CMR",{"label":16,"type":17,"description":18,"interventionNames":19},"Placebo","PLACEBO_COMPARATOR","Placebo daily X 7 days",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Dapagliflozin 10mg Tab","Dapagliflozin 10 mg daily X 7 days",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"DIAGNOSTIC_TEST","CMR","CMR 3-5 days post randomization",[16,9],[33],{"name":34,"affiliation":5,"role":35},"Michel LeMay, MD","PRINCIPAL_INVESTIGATOR",[37,43],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":42},"Poppy MacPhee, BScN","CONTACT","6136967000","14646","pmacphee@ottawaheart.ca",{"name":44,"role":39,"phone":45,"phoneExt":26,"email":46},"Tanya Abarbanel","613-696-7000","tabarbanel@ottawaheart.ca",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"University of Ottawa Heart Institute","RECRUITING","Ottawa","Ontario","K1Y 4W7","Canada","CA",{"type":57,"coordinates":58},"Point",[59,60],-75.69812,45.41117,{"lat":60,"lon":59},[63],{"name":64,"role":39,"phone":26,"phoneExt":26,"email":26},"Michel Le May",{"type":66,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100529513","phase-3-dapagliflozin-in-stemi-100529513",false,"NCT06174753","Dapagliflozin in STEMI","The University of Ottawa Dapagliflozin in STEMI Randomized Clinical Trial","DAPA STEMI","Inclusion Criteria:\n\nPatients referred for PPCI meeting the following criteria are eligible for the study:\n\n* Ischemic chest discomfort of ≥30 minutes duration, and\n* Onset of chest pain ≤12 hours prior to entry into the study, and\n* One of the following High-Risk criteria on a standard 12 lead ECG:\n\n  a. Anterior STEMI with ST-segment elevation ≥2mm (0.2 mV) in each of at least 2 contiguous precordial leads (V1-V6) b. Extensive non-anterior STEMI defined as ST-segment elevation of \\>1mm in two or more contiguous non-anterior leads accompanied by i. 8 or more leads with \\> 1 mm ST elevation or depression, or both; OR ii. Sum of ST- segment elevation \\>20mm\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Any contraindication to undergo CMR imaging\n* Killip 4 (Cardiogenic shock on presentation)\n* Therapy with SGLT2i within last 8 weeks\n* Type 1 diabetes mellitus\n* Pregnancy\n* Nursing mother\n* Unwilling to use appropriate forms of contraception, as applicable\n* Chronic symptomatic HF with prior hospitalization for HF within the last year\n* hospitalization\n* Known history of prior MI\n* Any non-CV condition with a life expectancy of less than one year\n* Previous randomization in the present study\n* Participation in a study with another investigational device or drug \\\u003C four weeks\n* Inability to provide informed consent\n* Confirmed ketoacidosis at time of admission\n* Known severe hepatic impairment (Cirrhosis)\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin1.73m2 (based on prior or baseline blood work)\n* Known severe valvular heart disease\n* Need for CABG within 90 days based on the results of the initial coronary angiogram\n* False positive STEMI (based on the results of the coronary angiogram)","ALL","18 Years",{"count":78,"type":79},256,"ESTIMATED","INTERVENTIONAL",[82],"PHASE3","The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI.\n\nEligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo.\n\nCardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.",[85,86],"ST Elevation Myocardial Infarction","Myocardial Infarction","2026-02-18",{"date":89,"type":90},"2026-02-20","ACTUAL",{"date":92,"type":90},"2025-01-20",{"date":94,"type":79},"2027-12",{"name":5,"class":6},1]